Anebulo Pharmaceuticals (ANEB) Stock Price, News & Analysis

Company Overview

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is based in Lakeway, Texas.

Key Stats

• Today's Range: $1.03 to $1.10
• 50-Day Range: $0.94 to $1.30
• 52-Week Range: $0.80 to $3.08
• Volume: 4,120 shs
• Average Volume: 18,536 shs
• Market Capitalization: $44.33 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $5.50
• Consensus Rating: Buy

Anebulo Pharmaceuticals Stock Analysis - MarketRank™

Anebulo Pharmaceuticals scored higher than 40% of companies evaluated by MarketBeat, and ranked 619th out of 939 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Anebulo Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Anebulo Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Anebulo Pharmaceuticals is -3.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Anebulo Pharmaceuticals is -3.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Anebulo Pharmaceuticals has a P/B Ratio of 7.10. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.14% of the float of Anebulo Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Anebulo Pharmaceuticals has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Anebulo Pharmaceuticals has recently increased by 0.60%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Anebulo Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Anebulo Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.14% of the float of Anebulo Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Anebulo Pharmaceuticals has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Anebulo Pharmaceuticals has recently increased by 0.60%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: N/A
• News Sentiment: N/A

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Anebulo Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

80.60% of the stock of Anebulo Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 28.40% of the stock of Anebulo Pharmaceuticals is held by institutions.

ANEB Stock Analysis - Frequently Asked Questions

How have ANEB shares performed this year?

Anebulo Pharmaceuticals' stock was trading at $1.68 at the start of the year. Since then, ANEB shares have decreased by 36.6% and is now trading at $1.0650.
View the best growth stocks for 2025 here.

How were Anebulo Pharmaceuticals' earnings last quarter?

Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) posted its earnings results on Tuesday, May, 13th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.05) by $0.01.

When did Anebulo Pharmaceuticals IPO?

Anebulo Pharmaceuticals (ANEB) raised $21 million in an IPO on Friday, May 7th 2021. The company issued 3,000,000 shares at a price of $6.00-$8.00 per share. The Benchmark Company acted as the underwriter for the IPO.

Who are Anebulo Pharmaceuticals' major shareholders?

Anebulo Pharmaceuticals' top institutional shareholders include LVW Advisors LLC (0.85%) and Goldman Sachs Group Inc. (0.12%).
View institutional ownership trends.

How do I buy shares of Anebulo Pharmaceuticals?

Shares of ANEB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Anebulo Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Anebulo Pharmaceuticals investors own include Hecla Mining (HL), Intra-Cellular Therapies (ITCI), Li Auto (LI), Norwegian Cruise Line (NCLH), PAR Technology (PAR), TransDigm Group (TDG) and Trade Desk (TTD).

Company Calendar

• Last Earnings: 5/13/2025
• Today: 6/05/2025
• Fiscal Year End: 6/30/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ANEB
• CIK: 1815974
• Web: www.anebulo.com
• Phone: 512-598-0931
• Fax: N/A
• Employees: 4
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $5.50
• High Stock Price Target: $8.00
• Low Stock Price Target: $3.00
• Potential Upside/Downside: +409.7%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.26)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$8.20 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -119.54%
• Return on Assets: -108.08%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 17.51
• Quick Ratio: 17.51

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.15 per share
• Price / Book: 7.19

Miscellaneous

• Outstanding Shares: 41,085,000
• Free Float: 5,793,000
• Market Cap: $44.33 million
• Optionable: Not Optionable
• Beta: -1.15